Safety Alerts & Recalls
What does this mean?
It is already known that HRT slightly increased the risk of ovarian cancer in some women, but this latest study appears to suggest that the risk may be greater than previously thought. The decision to start, continue or stop HRT should be made jointly by a woman and her doctor, based on the best advice available and her own personal circumstances, including age, need for treatment and medical risk factors. Women on HRT should have regular health check-ups and their need to continue treatment should be re-assessed at least annually. It is important that you do not stop taking your HRT unless advised to do so by your doctor. If you have any questions about the contents of this alert or your treatment with HRT you should discuss them with your doctor or other healthcare professional.
MHRA Advises Lowest Effective Dose of HRT Should Be Used for Shortest Possible Time
The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a statement in response to a recent study published in medical journal The Lancet. The study suggested that taking hormone replacement therapy (HRT) increases the risk of ovarian cancer. Dr Sarah Branch, deputy director of MHRA’s Vigilance and Risk Management of Medicines (VRMM) Division, said: “Our advice has always been that the lowest effective dose of HRT should be used for the shortest possible time. We will evaluate the findings of this study and its implications for shorter-term use and updated product information as necessary.” HRT is used to treat symptoms of the menopause.
For more information, please visit: more information here